Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Five Prime Therapeutics, Inc. for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Amgen Inc. . Under the terms of the agreement, Five Prime shareholders will receive only $38.00 in cash for each Five Prime share ...

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ:FPRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Amgen Inc. (NASDAQ:AMGN). Under the terms of the agreement, Five Prime shareholders will receive only $38.00 in cash for each Five Prime share that they own

The investigation concerns whether the Five Prime Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Amgen is paying too little for the Company.

If you own shares of Five Prime stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/five-prime-therapeutics-inc-nasdaq-fprx/, or call toll free 855-576-4847.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/633708/SHAREHOLDER-NOTICE-Brodsky-Smith-LLC-Announces-an-Investigation-of-Five-Prime-Therapeutics-Inc-Nasdaq--FPRX

News Provided by ACCESSWIRE IA via QuoteMedia

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

Keep reading... Show less

Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year

Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (ESG) issues. Amgen also was named to the DJSI North America Index for the ninth straight year.

The DJSI Indices are among the best indicators of a company's ESG performance due to the breadth of companies evaluated – nearly 11,000 this year – and the rigorous nature of the annual assessment process. The DJSI World Index recognizes the top 10% of companies in the S&P Global Broad Market Index for performance on ESG issues, which S&P Global considers critical to generating long-term stakeholder value.

Keep reading... Show less

Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

ASCENT Subgroup Analysis Provides Insights on Treatment Outcomes for Black Patients with Metastatic TNBC –

Separate ASCENT Post Hoc Analysis Examines Outcomes in Patients Who Discontinue Treatment Due to Progressive Disease

Keep reading... Show less

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting
Luxeptinib clinical update in AML and B-cell cancers

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 12 trial in patients with relapsed or refractory acute myeloid leukemia (AML). Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 ab trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS)

Keep reading... Show less

Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis

U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process

Keep reading... Show less

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

Top News

Related News